________________________________________________________
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.
NOTE: This Case Evaluation form can also be completed for situations that involve other incretin mimetic drugs which are used as diabetes medications, such as Januvia and/or Victoza -- even in there is no Byetta involved.
Diabetes drugs in the incretin mimetic class -- and their manufacturers --include:
Exenatide (Byetta, Bydureon / injection) -- Amylin, which was acquired by Bristol Myers Squibb (BMS), which co-markets with Astra-Zeneca (AZ);
Liraglutide (Victoza / injection) -- Novo Nordisk;
Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync / tablets) -- Merck;
Saxagliptin (Onglyza, Kombiglyze XR / tablets) -- BMS/AZ;
Alogliptin (Nesina, Kazano, Oseni / tablets) -- Takeda; and,
Linagliptin (Tradjenta, Jentadueto / tablets) -- Boehringer Ingelheim
________________________________________________________
My Articles About Byetta
As "Pancreatitis Is On The Pathway Toward Pancreatic Cancer", Medical Studies Needed To Determine If GLP-1 Diabetes Medications Linked To Cancers Or Malignancies Involving Pancreas
SUMMARY: In the last few weeks there has been an FDA alert about these diabetes drugs as well as a new significant medical journal article about a study concerning Byetta and Januvia which both have to do, in part, with the possible association between pancreatic cancer and the use of Victoza, Januvia, Byetta, etc.
It seems that the pancreatic cancer risk is becoming the real drug safety issue as regards Byetta, Januvia, Victoza, and the other incretin mimetic drugs for type 2 diabetes.
[Read this article in full at original source]
Earlier Byetta articles by Tom Lamb on the Drug Injury Watch blog:
